Joshua Cohen / Undark

Content Partner

More from Joshua Cohen / Undark

The agency’s decision of MDMA could slow down the timelines of getting psychedelics to market as other potential treatments, including psilocybin and ketamine, are likely to face similar regulatory challenges.

Health

How the FDA could shape the future of psychedelics research How the FDA could shape the future of psychedelics research

By Joshua Cohen / Undark

August 5, 2024